Eli Lilly is going after a market for a weight-loss drug before the company has even launched it. The pharma giant recently filed six new lawsuits as part of a coordinated enforcement effort against peptide sellers, a compounding pharmacy, and a medical spa that it says are selling or marketing retatrutide products. The problem, according to Lilly, the drug remains investigational. So, it has not been approved for human use by any regulatory agency, and Lilly does not commercially sell it.
The lawsuits – filed in California and Texas on August 12 – target Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide over their alleged sale and promotion of products purporting to contain retatrutide. In particular, Lilly alleges that the defendants are marketing unapproved retatrutide products for weight loss and other human uses, including products labeled “research use only.”
Lilly’s false advertising, unfair competition, and related state-law suits are an escalation in its campaign against sellers of unapproved retatrutide products and show that Lilly is moving to police a market that has emerged ahead of the drug’s potential launch.
Protecting a Market Before Launch
Lilly plans to seek U.S. approval for retatrutide in early 2027, and analysts are already projecting revenue of approximately $5.3 billion in 2030. At the same time, the drug has already gained widespread attention online, with purported retatrutide products promoted across social media, e-commerce sites, and other online channels. Against that background, the company is putting resources behind enforcement before the weight-loss drug can legally reach the market.
In addition to litigation, Lilly says it has referred hundreds of individuals and entities to regulators, law enforcement, and professional licensing boards and reported more than 14,000 websites, advertisements, social-media posts, and product listings marketing retatrutide across more than 100 countries. Its strategy also extends to the companies that enable those sellers to operate, with Lilly calling on social media and e-commerce platforms, credit card companies, payment processors, and shipping and logistics providers to cut off their access to those services.
The company is also increasingly turning to advertising challenges: Bloomberg Law reports that Lilly has brought at least five cases before the National Advertising Division against companies marketing compounded GLP-1 products.
What the Lawsuits Signal
For investors and competitors tracking the fast-growing obesity drug market, Lilly’s enforcement provides a measure of the resources it is putting behind retatrutide ahead of launch. The unauthorized market also cuts two ways: It points to consumer awareness and interest in retatrutide while the drug remains in clinical development, but requires Lilly to police a market it cannot yet legally participate in.
As for the latter part, Lilly has used a similar enforcement strategy with tirzepatide, the active ingredient in Mounjaro and Zepbound, pursuing unauthorized sellers through federal litigation and advertising challenges. With retatrutide, the company is applying that approach before regulatory approval. The effort could reduce the presence of unauthorized sellers by the time the drug reaches the market and give Lilly greater control over how retatrutide is sold and presented to consumers.
THE BOTTOM LINE: An unauthorized market for retatrutide has developed while the drug remains in clinical trials. Lilly is already working to reduce that market ahead of a potential launch.
Share
